Shots:
- Daiichi Sankyo & AstraZeneca has reported topline P-III (DESTINY-Breast11) trial data assessing neoadj. Enhertu (5.4mg/kg) monotx. or Enhertu followed by paclitaxel, Herceptin & Perjeta (THP) vs SoC + THP in high-risk, locally advanced HER2+ early-stage breast cancer pts (n=927)
- Trial showed that Enhertu regimen achieved significant improvement in pCR rate (1EP), while EFS (2EP) data was immature during analysis but indicated an early favorable trend & will be further assessed; data to be presented at future meetings & shared with global health authorities
- Pts enrollment in the 3rd arm of the study assessing Enhertu monotx. is closed following a recommendation from the IDMC, based on earlier interim efficacy findings of the study arms
Ref: Businesswire | Image: Daiichi Sankyo and AstraZeneca
Related News:- Daiichi Sankyo & AstraZeneca Report Topline P-III (DESTINY-Breast09) Trial Data of Enhertu for HER2+ Metastatic Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click Here for Full Press Release
